This contract is a modest positive for Cosmos Health's contract manufacturing segment but lacks disclosed financial terms (revenue, profit), making it difficult to size the bottom-line impact. Traders should monitor subsequent filings for revenue recognition or guidance updates that quantify the deal's contribution, and watch for additional contract wins that would validate segment momentum.
Price Chart
Executive Summary
Cosmos Health's subsidiary Cana Labs signed a three-year contract manufacturing deal with Verisfield to produce 1.3M units/year of VASCLOR GEST vaginal pessaries (total 3.9M units over three years). The agreement expands Cana's contract manufacturing business into women's health and adds a new customer, but no revenue or margin figures for the contract are disclosed.
Key Facts
- Cana Labs signed a three-year contract manufacturing agreement with Verisfield for VASCLOR GEST 400mg vaginal pessaries
- Annual production volume: 1.3 million units; total 3.9 million units over three years
- Expands Cana's contract manufacturing customer base into women's health and reproductive medicine
- Verisfield markets 60+ pharmaceutical products across seven therapeutic categories in Greece and internationally
Financial Impact
No revenue, pricing, margin, or profit figures disclosed — deal value not stated; broadly expands high-margin contract manufacturing segment by volume and customer diversification
Risk Factors
- No revenue or margin figures disclosed — economic value of the contract is unquantified
- Execution risk: manufacturing volumes may not materialize if Verisfield's demand changes or product launch is delayed
- Cosmos Health is a micro-cap ($13M market cap) — low liquidity and high volatility increase price risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3310067 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $0.2530 | awaiting T+20 | — | $0.2610 (+3.16%) |
Oct 16, 2026 10d ago | SC 13G/A | $0.3250 | awaiting T+20 | — | $0.2610 (−19.69%) |
Oct 9, 2026 17d ago | 8-K | $0.3496 | awaiting T+20 | — | $0.2610 (−25.34%) |
Sep 3, 2026 7w ago | Press Release | $0.2660 $0.4300 | ▼ −61.65% | ▼ −62.77% | $0.2610 (+1.88%) |
Aug 19, 2026 9w ago | Press Release | $0.1930 | awaiting T+20 | — | $0.2610 (−35.23%) |
Jul 20, 2026 14w ago | Press Release | $0.2303 $0.2050 | ▼ −10.99% | ▼ −15.11% | $0.2610 (+13.33%) |
Jul 17, 2026 14w ago | Press Release | $0.2348 $0.2179 | ▼ −7.20% | ▼ −11.64% | $0.2610 (+11.16%) |
Jul 16, 2026 14w ago | Press Release | $0.2807 $0.2065 | ▼ −26.43% | ▼ −30.05% | $0.2610 (−7.02%) |
Jul 15, 2026 14w ago | Press Release | $0.2785 $0.2071 | ▼ −25.64% | ▼ −27.98% | $0.2610 (−6.28%) |
Jul 14, 2026 14w ago | Press Release | $0.3071 $0.2198 | ▼ −28.43% | ▼ −30.92% | $0.2610 (−15.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers